Market revenue in 2023 | USD 145.0 million |
Market revenue in 2030 | USD 193.5 million |
Growth rate | 4.2% (CAGR from 2023 to 2030) |
Largest segment | Active tb |
Fastest growing segment | Active TB |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Active TB, Latent TB |
Key market players worldwide | AstraZeneca PLC, Johnson & Johnson, Eli Lilly and Co, Viatris Inc, Teva Pharmaceutical Industries Ltd, Sanofi SA, Novartis AG ADR, Sun Pharmaceutical Industries, Pfizer Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to tuberculosis therapeutics market will help companies and investors design strategic landscapes.
Active tb was the largest segment with a revenue share of 69.17% in 2023. Horizon Databook has segmented the Europe tuberculosis therapeutics market based on active tb, latent tb covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe tuberculosis therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Europe tuberculosis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account